{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:55:38Z","timestamp":1789390538927,"version":"build-2803163510"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Malignant melanoma is a serious disease in both humans and dogs, and the high metastatic potential results in poor prognosis for many patients. Its similarities with human melanoma make spontaneous canine melanoma an excellent model for comparative studies of novel therapies and tumor biology. Gene therapy using adenoviruses encoding the immunostimulatory gene CD40L (AdCD40L) has shown promise in initial clinical trials enrolling human patients with various malignancies including melanoma. We report a study of local AdCD40L treatment in 32 cases of canine melanoma (23 oral, 5 cutaneous, 3 ungual and 1 conjunctival). Eight patients were World Health Organization (WHO) stage I, 9 were stage II, 12 stage III, and 3 stage IV. One to six intratumoral injections of AdCD40L were given every seven days, combined with cytoreductive surgery in 20 cases and only immunotherapy in 12 cases. Tumor tissue was infiltrated with T and B lymphocytes after treatment, suggesting immune stimulation. The best overall response based on result of immunotherapy included 7 complete responses, 5 partial responses, 5 stable and 2 progressive disease statuses according to the World Health Organization response criteria. Median survival was 285 days (range 20\u20133435 d). Our results suggest that local AdCD40L therapy is safe and could have beneficial effects in dogs, supporting further treatment development. Clinical translation to human patients is ongoing.<\/jats:p>","DOI":"10.3389\/fvets.2021.695222","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T07:57:52Z","timestamp":1627027072000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas\u2013Long-Term Follow Up"],"prefix":"10.3389","volume":"8","author":[{"given":"Sara","family":"Saellstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Segall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dimopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Korsgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica SI.","family":"Loskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"T\u00f6tterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Ronnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"B1","first-page":"580","article-title":"Prognostic criteria for dogs with oral melanoma","volume":"178","author":"Harvey","year":"1981","journal-title":"J Am Vet Med Assoc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3109\/07357908609017520","article-title":"Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum","volume":"4","author":"MacEwen","year":"1986","journal-title":"Cancer Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/030098587901600103","article-title":"Prognosis after surgical excision of canine melanomas","volume":"16","author":"Bostock","year":"1979","journal-title":"Vet Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"626129","DOI":"10.3389\/fonc.2020.626129","article-title":"Decoding melanoma development and progression: identification of therapeutic vulnerabilities","volume":"10","author":"Eddy","year":"2020","journal-title":"Front Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1053\/j.tcam.2015.06.001","article-title":"Melanocytic ophthalmic neoplasms of the domestic veterinary species: a review","volume":"30","author":"Wang","year":"2015","journal-title":"Top Companion Anim Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/030098588602300411","article-title":"Morphology and behavior of primary ocular melanomas in 91 dogs","volume":"23","author":"Wilcock","year":"1986","journal-title":"Vet Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1354\/vp.43-2-136","article-title":"The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia","volume":"43","author":"Spangler","year":"2006","journal-title":"Vet Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/jcpa.1998.0291","article-title":"PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs","volume":"121","author":"Roels","year":"1999","journal-title":"J Comp Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3389\/fonc.2019.01397","article-title":"Array comparative genomic hybridization analysis reveals significantly enriched pathways in canine oral melanoma","volume":"9","author":"Brocca","year":"2019","journal-title":"Front Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/genes10070501","article-title":"Canine melanomas as models for human melanomas: clinical, histological, and genetic comparison","volume":"10","author":"Prouteau","year":"2019","journal-title":"Genes."},{"key":"B11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/ijms19020394","article-title":"Naturally occurring canine melanoma as a predictive comparative oncology model for human mucosal and other triple wild-type melanomas","volume":"19","author":"Hernandez","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3389\/fonc.2019.01148","article-title":"Immune system evasion as hallmark of melanoma progression: the role of dendritic cells","volume":"9","author":"Tucci","year":"2019","journal-title":"Front Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.3390\/ijms21238984","article-title":"Overcoming immune evasion in melanoma","volume":"21","author":"Eddy","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vetimm.2015.11.003","article-title":"Cancer immunology and canine malignant melanoma: a comparative review","volume":"169","author":"Atherton","year":"2016","journal-title":"Vet Immunol Immunopathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3892\/ijmm.2020.4736","article-title":"Oral cancer cellderived exosomes modulate natural killer cell activity by regulating the receptors on these cells","volume":"46","author":"Zhu","year":"2020","journal-title":"Int J Mol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3747\/co.v16i3.367","article-title":"Exosomes in tumour immunity","volume":"16","author":"Clayton","year":"2009","journal-title":"Curr Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/jsap.12336","article-title":"Immunotherapy for canine cancer-is it time to go back to the future?","volume":"56","author":"Killick","year":"2015","journal-title":"J Small Anim Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/JTO.0b013e3182037b76","article-title":"The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer","volume":"6","author":"Bremnes","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2011.00098","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2011","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00281-016-0592-y","article-title":"The role of dendritic cells in cancer","volume":"39","author":"Hansen","year":"2017","journal-title":"Semin Immunopathol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2174\/1568009614666140828103253","article-title":"The role of CD40 expression in dendritic cells in cancer biology; a systematic review","volume":"14","author":"Lee","year":"2014","journal-title":"Curr Cancer Drug Targets."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.3390\/v7112899","article-title":"Immunostimulatory gene therapy using oncolytic viruses as vehicles","volume":"7","author":"Loskog","year":"2015","journal-title":"Viruses."},{"key":"B23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41467-017-01572-7","article-title":"Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain","volume":"8","author":"Singh","year":"2017","journal-title":"Nat Commun."},{"key":"B25","first-page":"1287","article-title":"Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis","volume":"59","author":"von Leoprechting","year":"1999","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0b013e31829d8a1b","article-title":"Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma","volume":"36","author":"Westberg","year":"2013","journal-title":"J Immunother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/CJI.0b013e31816a812d","article-title":"Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma","volume":"31","author":"von Euler","year":"2008","journal-title":"J Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/bjc.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Loskog","year":"2016","journal-title":"Br J Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12967-017-1182-z","article-title":"Adenovirus-mediated CD40L gene transfer increases Teffector\/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients","volume":"15","author":"Schiza","year":"2017","journal-title":"J Transl Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3109\/14653249.2011.592523","article-title":"Comparison of two CD40-ligand\/interleukin-2 vaccines in patients with chronic lymphocytic leukemia","volume":"13","author":"Okur","year":"2011","journal-title":"Cytotherapy."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers."},{"key":"B32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/vco.283","volume":"14","year":"2016","journal-title":"Vet Comp Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/nbt1209-1135","article-title":"How does multiple testing correction work?","volume":"27","author":"Noble","year":"2009","journal-title":"Nat Biotechnol."},{"key":"B36","volume-title":"TNM Classification of Tumours in Domestic Animals","author":"Owen","year":"1980"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.18632\/oncotarget.23967","article-title":"Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients","volume":"9","author":"Taipale","year":"2018","journal-title":"Oncotarget."},{"key":"B38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1354\/vp.37-6-597","article-title":"Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases","volume":"37","author":"Ramos-Vara","year":"2000","journal-title":"Vet Pathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1053\/j.ctsap.2007.03.004","article-title":"Canine oral melanoma","volume":"22","author":"Bergman","year":"2007","journal-title":"Clin Tech Small Anim Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cvsm.2019.04.010","article-title":"Cancer immunotherapies","volume":"49","author":"Bergman","year":"2019","journal-title":"Vet Clin North Am Small Anim Pract."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12690","article-title":"Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: a retrospective study on 155 cases","author":"Giacobino","year":"2021","journal-title":"Vet Comp Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","article-title":"Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center","volume":"24","author":"Bergman","year":"2006","journal-title":"Vaccine."},{"key":"B43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00262-005-0025-6","article-title":"Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma","volume":"55","author":"Alexander","year":"2006","journal-title":"Cancer Immunol Immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/mt.2014.7","article-title":"A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology","volume":"22","author":"Laborda","year":"2014","journal-title":"Mol Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/cancers10110404","article-title":"Oncolytic viruses for canine cancer treatment","volume":"10","author":"Sanchez","year":"2018","journal-title":"Cancers."},{"key":"B46","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/cgt.2012.72","article-title":"Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up","volume":"19","author":"Finocchiaro","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2020.11.FOCUS20844","article-title":"Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas","volume":"50","author":"Omar","year":"2021","journal-title":"Neurosurg Focus."},{"key":"B48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1046\/j.1365-3164.2001.00236.x","article-title":"MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma","volume":"12","author":"Laprie","year":"2001","journal-title":"Vet Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma\u2013the first phase I\/IIa trial","volume":"16","author":"Malmstrom","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1939-1676.2011.00883.x","article-title":"Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer","volume":"26","author":"Mitchell","year":"2012","journal-title":"J Vet Intern Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cvsm.2014.06.001","article-title":"Small molecule inhibitors in veterinary oncology practice","volume":"44","author":"London","year":"2014","journal-title":"Vet Clin North Am Small Anim Pract."},{"key":"B52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/0300985810388947","article-title":"Prognostic evaluation of Ki67 threshold value in canine oral melanoma","volume":"48","author":"Bergin","year":"2011","journal-title":"Vet Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1354\/vp.45-6-889","article-title":"Survival of dogs following surgical excision of histologically well-differentiated melanocytic neoplasms of the mucous membranes of the lips and oral cavity","volume":"45","author":"Esplin","year":"2008","journal-title":"Vet Pathol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/104063870601800422","article-title":"Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs","volume":"18","author":"Schultheiss","year":"2006","journal-title":"J Vet Diagn Invest."},{"key":"B55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CMR.0000000000000571","article-title":"Amelanotic melanoma","volume":"29","author":"Gong","year":"2019","journal-title":"Melanoma Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamadermatol.2014.1348","article-title":"Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study","volume":"150","author":"Thomas","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.tvjl.2013.09.020","article-title":"Longevity and mortality of owned dogs in England","volume":"198","author":"O'Neill","year":"2013","journal-title":"Vet J."},{"key":"B58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2460\/javma.1995.207.06.0726","article-title":"Evaluation of dogs with digit masses: 117 cases (1981\u20131991)","volume":"207","author":"Marino","year":"1995","journal-title":"J Am Vet Med Assoc."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF00046339","article-title":"Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment","volume":"9","author":"MacEwen","year":"1990","journal-title":"Cancer Metastasis Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1748-5827.1975.tb05729.x","article-title":"The role of spontaneous canine tumours in the evaluation of the aetiology and therapy of human cancer","volume":"16","author":"Owen","year":"1975","journal-title":"J Small Anim Pract."},{"key":"B62","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.trsl.2011.11.005","article-title":"Canine tumors: a spontaneous animal model of human carcinogenesis","volume":"159","author":"Pinho","year":"2012","journal-title":"Transl Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3109\/07357900009012210","article-title":"Spontaneously occurring tumors of companion animals as models for human cancer","volume":"18","author":"Vail","year":"2000","journal-title":"Cancer Invest."},{"key":"B64","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2273","article-title":"Translation of new cancer treatments from pet dogs to humans","volume":"8","author":"Paoloni","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"B65","first-page":"1284","article-title":"Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial","volume":"9","author":"Bergman","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s42003-021-01698-x","article-title":"A novel canine reference genome resolves genomic architecture and uncovers transcript complexity","volume":"4","author":"Wang","year":"2021","journal-title":"Commun Biol."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2021.695222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T22:10:42Z","timestamp":1725487842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2021.695222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":66,"alternative-id":["10.3389\/fvets.2021.695222"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2021.695222","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"article-number":"695222"}}